Blood Test May Match CT for Early Lung Cancer Detection
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
The Nu.Q Cancer Test distinguished between malignant and benign pulmonary nodules detected by LDCT scans in suspected lung cancer.
A blood test identifies early lung damage in cancer patients taking antibody–drug conjugates, offering an alternative to imaging scans.
Read MoreThe system enables detection and personalized care for diseases like Cystic Fibrosis, Chronic Obstructive Pulmonary Diseases, and lung cancer.
Read MoreResearchers developed a sensor that can detect low levels of isoprene in exhaled breath, potentially enabling early lung cancer diagnosis.
Read MoreNeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MoreBioAffinity Technologies’ noninvasive lung cancer test is available to Veterans and military personnel for early-stage lung cancer detection.
Read MoreA new microchip uses exosome analysis to detect lung cancer from a simple blood draw, enhancing speed and sensitivity in cancer diagnostics.
Read MoreThe MET Predict assists in identifying NSCLC tumors with MET exon 14 skipping or MET amplification directly from H&E whole slide images.
Read MoreSummary: DELFI Diagnostics appointed Thomas Russo as its new CFO to support the company’s...
Read MoreA new AI-driven digital pathology platform enables fully automated, rapid, and accurate analysis of lung cancer tissue.
Read MoreSeveral diagnostic associations announced the open comment period for the revised 2018 guideline on molecular testing for lung cancer.
Read MoreA new study from OncoHost reveals that its PROphetNSCLC test impacts oncologists’ first-line treatment decisions for metastatic NSCLC.
Read MoreResearchers have developed a potential exhaled-breath test for lung diseases by successfully collecting lung biomarkers from human breath.
Read MoreResearchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read MoreDELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read MoreOncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More